Dr. Reddy's Laboratories Limited vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends

Pharma Giants' SG&A Expenses: A Decade of Divergence

__timestampACADIA Pharmaceuticals Inc.Dr. Reddy's Laboratories Limited
Wednesday, January 1, 20143274800038783000000
Thursday, January 1, 20159080400042585000000
Friday, January 1, 201618645600045702000000
Sunday, January 1, 201725506200046372000000
Monday, January 1, 201826575800046910000000
Tuesday, January 1, 201932563800048890000000
Wednesday, January 1, 202038866100050129000000
Friday, January 1, 202139602800054559000000
Saturday, January 1, 202236909000062081000000
Sunday, January 1, 2023402466000105931000000
Monday, January 1, 202477201000000
Loading chart...

In pursuit of knowledge

SG&A Expense Trends: A Tale of Two Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Dr. Reddy's Laboratories Limited and ACADIA Pharmaceuticals Inc. from 2014 to 2023. Over this period, Dr. Reddy's Laboratories consistently outspent ACADIA, with expenses peaking at over 105 billion in 2023, a staggering 170% increase from 2014. In contrast, ACADIA's expenses grew by approximately 1,130%, reaching 402 million in 2023. This disparity highlights the scale and operational differences between the two companies. Notably, Dr. Reddy's experienced a significant drop in 2024, indicating potential strategic shifts or market challenges. Missing data for ACADIA in 2024 suggests a need for further investigation. These insights provide a window into the financial strategies shaping the pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025